Re: Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial
- 1 June 2023
- journal article
- editorial
- Published by Elsevier BV in European Urology
- Vol. 83 (6), 580
- https://doi.org/10.1016/j.eururo.2023.01.008
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Device-assisted intravesical chemotherapy treatment for nonmuscle invasive bladder cancer: 2022 updateCurrent Opinion in Urology, 2022
- European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)European Urology, 2021
- Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non–muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled TrialEuropean Urology, 2018
- Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non–Muscle-invasive Bladder CancerEuropean Urology, 2016
- Multicentric Study Comparing Intravesical Chemotherapy Alone and With Local Microwave Hyperthermia for Prophylaxis of Recurrence of Superficial Transitional Cell CarcinomaJournal of Clinical Oncology, 2003